Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AtriCure Inc is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. AtriCure employs 875 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $40.86 |
|---|---|
| 52-week range | $32.84 - $89.18 |
| 50-day moving average | $46.30 |
| 200-day moving average | $63.47 |
| Wall St. target price | $78.60 |
| PE ratio | 35.1515 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $40.86 from 2022-06-30
| 1 week (2022-06-24) | -0.15% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-04-01) | -38.10% |
| 6 months (2021-12-28) | N/A |
| 1 year (2021-07-01) | -49.57% |
|---|---|
| 2 years (2020-07-01) | -9.74% |
| 3 years (2019-07-01) | 33.62% |
| 5 years (2017-06-30) | 68.49% |
Valuing AtriCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AtriCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AtriCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, AtriCure shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $289.6 million |
|---|---|
| Gross profit TTM | $205.9 million |
| Return on assets TTM | -4.68% |
| Return on equity TTM | 12.16% |
| Profit margin | 17.93% |
| Book value | $10.00 |
| Market capitalisation | $1.8 billion |
TTM: trailing 12 months
We're not expecting AtriCure to pay a dividend over the next 12 months.
Over the last 12 months, AtriCure's shares have ranged in value from as little as $32.84 up to $89.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 1.2114. This would suggest that AtriCure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.